Indofarma (Persero) Tbk PT operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Indofarma (Persero) Tbk PT with three other
pharmaceutical manufacturers in Asia:
Changzhou Qianhong Biopharma Co., Ltd.
sales of 776.38 million Chinese Renmimbi [US$122.30 million]
of which 100%
was Bio-pharmaceutical Industry),
JW Life Science Corp
of South Korea
(132.29 billion Korean Won [US$123.56 million]
Dawnrays Pharmaceutical (Holdings) Ltd
based in Hong Kong
(961.65 million Hong Kong Dollars [US$122.93 million]
of which 80%
was Finished Drugs).
During the year ended December of 2016, sales at
Indofarma (Persero) Tbk PT were 1.67 trillion Indonesian Rupiahs (US$122.92 million).
increase of 3.3%
versus 2015, when the company's sales were 1.62 trillion Indonesian Rupiahs.
This was the fourth straight year of sales growth at Indofarma (Persero) Tbk PT.